natgillin/translations-raw huggingface dataset:
SUSTIVA has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts &lt; 50 cells/mm3, or after failure of protease inhibitor (PI) containing regimens.
SUSTIVA nije adekvatno ispitana u bolesnika s uznapredovalom HIV bolešću, odnosno u bolesnika s brojem CD4 &lt; 50stanica/mm3 ili u onih u kojih nije uspjelo liječenje protokolima s inhibitorom proteaze (IP).
SVR rates were &gt; 94% across combination antiretroviral therapy (cART) regimens, including boosted-PI-, NNRTI-, and integrase inhibitor (INSTI)-based therapies.
Stope SVR-a bile su &gt; 94% uz sve režime kombinirane antiretrovirusne terapije, uključujući terapije utemeljene na pojačanom inhibitoru proteaze, nenukleozidnom inhibitoru reverzne transkriptaze (NNRTI) i inhibitoru integraze (INSTI).
Switching to Eviplera was non-inferior in maintaining HIV-1 RNA &lt; 50 copies/mL when compared to patients who stayed on a ritonavir-boosted protease inhibitor in combination with two NRTIs [Treatment difference (95% CI): + 3.8% (-1.6% to 9.1%)].
Prebacivanje na lijek Eviplera je bilo neinferiorno u održavanju razina HIV-1 RNK &lt; 50 kopija/ml u usporedbi s pacijentima koji su ostali na ritonavirom pojačanom inhibitoru proteaze u kombinaciji s dva NRTI-ja [razlika između liječenja (95% CI):+ 3,8% (-1,6% do 9,1%)].
Symptomatic treatment of patients with severe COPD (FEV1 &lt; 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Simptomatsko liječenje bolesnika s teškom KOPB (FEV1 &lt; 50% od predviđene normale) i anamnezom ponavljanih egzacerbacija, koji imaju značajne simptome unatoč redovnoj terapiji bronhodilatatorima dugog djelovanja.
Symptoms of hypoglycaemia (unconfirmed by blood glucose levels) were observed in patients whose baseline HbA1c was close to the therapeutic target (HbA1c &lt; 7.5%).
Simptomi hipoglikemije (koja nije bila potvrđena razinama glukoze u krvi) bili su uočeni u bolesnika čiji je početni HbA1c bio blizu cilju terapije (HbA1c &lt; 7,5%).
Systemic allergy is rare ( 1/10,000 to &lt; 1/1,000).
Sistemska alergijska reakcija je rijetka (≥ 1/10 000 i &lt; 1/1000).
Systemic exposure from topical application of tacrolimus ointment is low ( &lt; 1.0 ng/ml) and is unlikely to be affected by concomitant use of substances known to be inhibitors of CYP3A4.
Sistemska izloženost nakon topikalne primjene takrolimus masti je niska ( &lt; 1,0 ng/ml) i na nju najvjerojatnije neće utjecati istovremena primjena tvari za koje se zna da inhibiraju CYP3A4.
Systemic exposure to retapamulin has been low following topical application of 10 mg/g ointment in adult and paediatric patients aged 2 years and older (maximum plasma concentration &lt; 20 ng/mL).
Nakon topikalne primjene 10 mg/g masti u odraslih i pedijatrijskih bolesnika u dobi od 2 i više godina, sistemska izloženost retapamulinu bila je niska (maksimalna koncentracija u plazmi &lt; 20 ng/ml).
Systemic exposures after a single dose of sunitinib were similar in subjects with severe renal impairment (CLcr &lt; 30 ml/min) compared to subjects with normal renal function (CLcr &gt; 80 ml/min).
Sustavna izloženost nakon jedne doze sunitiniba bila je podjednaka u ispitanika s teškim oštećenjem bubrežne funkcije (CLcr &lt; 30 ml/min) i ispitanika s normalnom bubrežnom funkcijom (CLcr &gt; 80 ml/min).
systolic blood pressure at entry &gt; 160 mmHg
sistolički krvni tlak na početku liječenja &gt; 160 mmHg
Systolic BP ≥140 mmHg up to &lt; 160 mmHg or diastolic BP ≥90 mmHg up to &lt; 100 mmHg
Sistolički KT ≥140 mmHg do &lt; 160 mmHg ili dijastolički KT ≥90 mmHg do &lt; 100 mmHg
Table 1 Adverse events and laboratory abnormalities with incidence rates ≥10% and the respective percentages under placebo; significantly associated side effects &lt; 10% based on reports from clinical trials
Tablica 1 Štetni događaji i laboratorijske abnormalnosti sa stopama incidencije ≥10% i pripadajući postotci za placebo; u značajnoj mjeri povezane nuspojave &lt; 10% na temelju izvješća iz kliničkih ispitivanja
Table 1 contains very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10) and uncommon (≥ 1/1000, &lt; 1/100) adverse reactions which occurred in clinical trials.
Tablica 1 sadrži vrlo česte (≥ 1/10), česte (≥ 1/100 do &lt; 1/10) i manje česte (≥ 1/1000, &lt; 1/100) nuspojave koje su se pojavljivale u kliničkim ispitivanjima.
Table 1 contains very common (≥ 1/10), common (≥ 1/100, &lt; 1/10); uncommon (≥ 1/1000, &lt; 1/100); rare (≥ 1/10,000, &lt; 1/1,000) adverse reactions which occurred in clinical trials and a post- marketing surveillance survey.
Tablica 1 sadrži vrlo često (≥ 1/10), često (≥ 1/100, &lt; 1/10), manje često (≥ 1/1000, &lt; 1/100); i rijetko (≥ 1/10,000, &lt; 1/1,000) nuspojave koje su se javile u kliničkim ispitivanjima i izvješćima nakon stavljanja lijeka u promet.
Table 1 presents adverse reactions listed by system organ class and frequency categories, using the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), and uncommon (≥1/1,000 to
Tablica 1 prikazuje nuspojave prema klasifikaciji organskih sustava i kategorijama učestalosti sukladno sljedećoj konvenciji: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10) i manje često (≥1/1000 i
Table 17: Virologic response post-transplant in subjects with HCV RNA &lt; LLOQ at the time of liver transplantation
Tablica 17: Virološki odgovor nakon transplantacije u ispitanika s HCV RNK &lt; donje granice kvantifikacije u vrijeme transplantacije jetre
Table 1: Adverse events and laboratory abnormalities with incidence rates ≥ 10% and the respective percentages under placebo; significantly associated side effects &lt; 10% based on reports from clinical trials
Štetni događaji i laboratorijske abnormalnosti sa stopama incidencije ≥ 10 % i pripadajući postotci za placebo; značajno povezane nuspojave &lt; 10 % temeljeno na podacima iz kliničkih ispitivanja.
Table 1: Adverse reactions (reported in at least 2 patients) and adverse reactions reported in post- marketing setting, expanded access programs and non-controlled clinical trials, per System Organ Class, presented by frequency categories: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Tablica 1: Nuspojave (prijavljene u najmanje 2 bolesnika) i nuspojave prijavljene nakon stavljanja lijeka u promet te u programima proširenog pristupa i nekontroliranim kliničkim ispitivanjima klasificirane prema organskim sustavima i kategorijama učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Table 1: Dosing for paediatric patients aged 2 to &lt; 12 years
Tablica 1: Doziranje kod pedijatrijskih pacijenata u dobi od 2 do &lt; 12 godina
Table 1: Seroprotection Rates to Measles, Mumps, and Rubella 6 Weeks Post-Dose 1 and 6 Weeks Post-Dose 2 of the quadrivalent measles, mumps, rubella and varicella vaccine manufactured by Merck &amp; Co., Inc. – Full Analysis Set
Tablica 1: stopa seropotekcije za virus morbila, parotitisa i rubele 6 tjedana nakon primjene 1. doze i 6 tjedana nakon 2. doze kvadrivalentnog cjepiva protiv morbila, parotitisa, rubele i varičela proizvođača Merck &amp; Co., Inc. – analiza cjelokupnih podataka
Table 2 Injection volumes of STELARA for paediatric psoriasis patients &lt; 60 kg
Tablica 2: Injekcijski volumeni STELARE za pedijatrijske bolesnike s psorijazom &lt; 60 kg
Table 2 lists the adverse reactions according to MedDRA system organ class and frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to
Tablica 2 navodi nuspojave prema MedDRA klasifikaciji organskih sustava i učestalosti na sljedeći način: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i
Table 2 presents adverse reactions listed by system organ class and frequency categories, using the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to
Tablica 2 prikazuje nuspojave prema klasifikaciji organskih sustava i kategorijama učestalosti sukladno sljedećoj konvenciji: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i
Table 2 Proportion of patients who achieved target serum uric acid levels ( &lt; 6 mg/dL) with Zurampic in combination with allopurinol - Pooled data from CLEAR1 and CLEAR2 studies
Tablica 2 Udio bolesnika koji su postigli ciljne razine mokraćne kiseline u serumu ( &lt; 6 mg/dl) uz primjenu lijeka Zurampic u kombinaciji s alopurinolom – združeni podaci iz ispitivanja CLEAR1 i CLEAR2
Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data) for VTEp, NVAF, and VTEt respectively.
Tablica 2 prikazuje nuspojave kod VTEp, NVAF i VTEt, razvrstane prema klasifikaciji organskih sustava i učestalosti u sljedeće kategorije: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Table 2 Summary of PASI 50/75/90/100 &amp; IGA⃰ mod 2011 “clear” or “almost clear” clinical response in Psoriasis Studies 1, 3 and 4 (ERASURE, FEATURE and JUNCTURE)
Tablica 2 Sažetak kliničkih odgovora PASI 50/75/90/100 i IGA⃰ mod 2011 „čista“ ili „gotovo čista“ u prvom, trećem i četvrtom ispitivanju psorijaze (ERASURE, FEATURE i JUNCTURE)
Table 3 Proportion of patients with baseline sUA ≥5.0 mg/dLwho achieve target serum uric acid levels ( &lt; 5 mg/dL) with Zurampic in combination with febuxostat
Tablica 3 Udio bolesnika s početnom vrijednosti sUA &gt; 5,0 mg/dl koji su postigli ciljne razine mokraćne kiseline u serumu ( &lt; 5 mg/dl) uz liječenje lijekom Zurampic u kombinaciji s febuksostatom
Table 3 Response in SPRING-2 and SINGLE at 48 Weeks (Snapshot algorithm, &lt; 50 copies/mL)
Tablica 3 Odgovori u ispitivanjima SPRING-2 i SINGLE nakon 48 tjedana (algoritam za globalnu snimku distribuiranog sustava [engl. snapshot algorithm], &lt; 50 kopija/ml)
Table 3 Summary of Pharmacokinetic Parameters of ADVATE per Age Group with severe haemophilia A (baseline factor VIII &lt; 1%)
Tablica 3 Sažetak farmakokinetičkih parametara lijeka ADVATE po dobnim skupinama bolesnika s teškom hemofilijom A (početna vrijednost faktora VIII &lt; 1%)
Table 4 Response in SAILING at 48 Weeks (Snapshot algorithm, &lt; 50 copies/mL)
Tablica 4 Odgovori u ispitivanju SAILING nakon 48 tjedana (algoritam za globalnu snimku distribuiranog sustava, &lt; 50 kopija/ml)
Table 4 shows the adverse reactions ranked under headings of System Organ Classes (SOC) and frequency using the following convention: very common ( 1/10), common (1 /100 to &lt; 1 /10), uncommon ( 1/1,000 to &lt; 1 /100), rare (1 /10,000 to &lt; 1 /1,000), very rare ( &lt; 1 /10,000), not known (cannot be estimated from the available data).
Tablica 4 prikazuje nuspojave poredane prema klasifikaciji organskih sustava i učestalosti, uz sljedeću konvenciju: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1 000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1 000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se utvrditi iz dostupnih podataka).
Table 4: Exposure adjusted Grade 3 &amp; 4 laboratory abnormalities among patients on Fuzeon+OB and OB alone regimens, reported at more than 2 patients with event per 100 patient years
Tablica 4: Laboratorijska odstupanja stupnja 3 i 4 prilagođena u odnosu na izloženost u bolesnika liječenih režimom Fuzeon + OT, odnosno samo OT, prijavljena u više od 2 bolesnika s nuspojavom na 100 bolesnik-godina
Table 5: Proportion of subjects with &lt; 50 HIV-1 RNA copies/ml at week 48 by baseline number of INTELENCE RAMs in the non-viral failure excluded population of pooled DUET-1 and DUET-2 trials
Tablica 5: Udio ispitanika s &lt; 50 HIV-1 RNK &lt; 50 kopija/ml u 48. tjednu prema početnom broju mutacija povezanih s rezistencijom (RAM) na INTELENCE u populaciji iz koje nisu isključeni ispitanici s virološkim neuspjehom prema združenim podacima ispitivanja DUET-1 i DUET-2
Table 6 Proportion of Patients achieving &lt; 400 copies/ml and &lt; 50 copies/ml at Week 48 by subgroup (pooled TORO 1 and TORO 2, ITT)
Tablica 6 Udio bolesnika koji su postigli &lt; 400 kopija/ml i &lt; 50 kopija/ml u 48. tjednu po podskupinama (objedinjeni podaci iz TORO 1 i TORO 2, ITT)
Table 6: Comparative analysis between 7-valent Prevenar and Synflorix in percentage of subjects with antibody concentrations &gt; 0.20 µg/ml one month post-dose 3
Tablica6: Komparativna analiza 7-valentnog cjepiva Prevenar i cjepiva Synflorix u postotku ispitanika s koncentracijom protutijela &gt; 0,20 µg/ml jedan mjesec nakon 3. doze
Table 6: Proportion of patients achieving &lt; 50 copies/mL at Week 48 by subgroup (pooled Studies MOTIVATE 1 and MOTIVATE 2)
Tablica 6: Udio bolesnika u pojedinim podskupinama u kojih je u 48. tjednu postignuto 50 kopija/ml (zajednički podaci ispitivanja MOTIVATE 1 i MOTIVATE 2)
Table 6: SCR and GMT at four weeks after a single 6 mcg booster dose administered to subjects with a PRNT50 &lt; 1:10 (PRNT50 &lt; 1:10 means a subject is no longer seroprotected) at month 11 or month 23 after recommended primary immunization (2x 6 mcg) or incomplete (1x6 mcg) primary immunization with IXIARO (ITT population)
Tablica 6 Stopa serokonverzije (SCR) i geometrijska sredina titra (GMT) u četvrtom tjednu nakon docjepljivanja s jednom dozom od 6 μg u ispitanika s PRNT50 &lt; 1:10 (PRNT50 &lt; 1:10 znači da ispitanik više nije serološki zaštićen) u 11. mjesecu ili 23. mjesecu nakon preporučene primarne imunizacije (2x 6 μg) ili nepotpune (1x6 μg) primarne imunizacije cjepivom IXIARO (ITT populacija)
Table 7: Symptom outcomes for GIOTRIF vs. chemotherapy in trials LUX-Lung 3 and LUX-Lung 6 (EORTC QLQ-C30 &amp; QLQ-LC13)
Tablica 7: Ishodi simptoma za GIOTRIF naspram kemoterapije u ispitivanjima LUX-Lung 3 i LUX-Lung 6 (EORTC QLQ-C30 i QLQ-LC13)
Table 9: Symptom outcomes for GIOTRIF vs. erlotinib in trial LUX-Lung 8 (EORTC QLQ-C30 &amp; QLQ-LC13)
Tablica 9: Ishodi vezani uz simptome za GIOTRIF naspram erlotiniba u ispitivanju LUX-Lung 8 (EORTC QLQ-C30 &amp; QLQ-LC13)
Tablet coating for 300 mg/25 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, Indigotine (Indigo carmine aluminium lake FD &amp; C blue #2) and iron oxide black.
Ovojnica za 300 mg/25 mg tablete: hipromeloza, titanijev dioksid, polietilenglikol 6000 (makrogol), polietilenglikol 400 (makrogol), crveni željezov oksid, indigotin (Indigo carmine aluminium lake FD &amp; C plava #2) i crni željezov oksid.
Tadalafil 40 mg increased cardiac output (0.6 L/min) and reduced pulmonary artery pressures (-4.3 mmHg) and pulmonary vascular resistance (-209 dyn.s/cm5) compared to baseline (p &lt; 0.05).
Tadalafil u dozi od 40 mg je povećao minutni volumen srca (0,6 l/min) te snizio plućni arterijski tlak (-4,3 mmHg) i plućni krvožilni otpor (-209 dyn.s/cm5) u odnosu na početne vrijednosti (p &lt; 0,05).
Tadalafil is &gt; 10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4 enzymes which are found in the heart, brain, blood vessels, liver, and other organs.
Tadalafil djeluje &gt; 10 000 puta jače na PDE5 nego na PDE1, PDE2 i PDE4, enzime koji se nalaze u srcu, mozgu, krvnim žilama, jetri i drugim organima.
Tadalafil is &gt; 10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4, enzymes which are found in the heart, brain, blood vessels, liver, and other organs.
Tadalafil djeluje &gt; 10 000 puta jače na PDE5 nego na PDE1, PDE2 i PDE4, enzime koji se nalaze u srcu, mozgu, krvnim žilama, jetri i drugim organima.
Tadalafil is &gt; 10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels.
Tadalafil djeluje &gt; 10 000 puta jače na PDE5 nego na PDE3, enzim koji se nalazi u srcu i krvnim žilama.
Tadalafil is also &gt; 10,000-fold more potent for PDE5 than for PDE7 through PDE10.
Tadalafil također djeluje &gt; 10 000 puta snažnije na PDE5 nego na PDE7 do PDE10.
Tadalafil is also &gt; 10,000-fold more potent for PDE5 than for PDE7 through PDE10.
Tadalafil također djeluje &gt; 10,000 puta jače snažnije na PDE5 nego na enzime PDE7 do PDE10.
Tadalafil is also &gt; 10,000-fold more potent for PDE5 than for PDE7 through PDE10.
Tadalafil također djeluje &gt; 10,000 puta snažnije na PDE5 nego na enzime PDE7 do PDE10.
Taking the extremes of body weight into consideration, from &lt; 43 kg to &gt; 90 kg, AZ5104 metabolite ratios ranged from 11.8% to 9.6% while for AZ7550 it ranged from 12.8% to 9.9%, respectively.
Uzimajući u obzir ekstreme tjelesne težine, od &lt; 43 kg do &gt; 90 kg, omjeri metabolita AZ5104 bili su u rasponu od 11,8% do 9,6%, dok su za metabolit AZ7550 bili u rasponu od 12,8% do 9,9%.
Taltz was associated with a fast onset of efficacy with &gt; 50 % reduction in mean PASI by Week 2 (Figure 1).
Taltz je bio povezan s brzim nastupom djelotvornosti, uz smanjenje srednje vrijednosti PASI rezultata za &gt; 50% do 2. tjedna (Slika 1).
Telbivudine is eliminated primarily by renal excretion, therefore dose interval adjustment is recommended in patients with creatinine clearance &lt; 50 ml/min, including patients on haemodialysis.
Telbivudin se eliminira prvenstveno izlučivanjem putem bubrega te se stoga preporučuje prilagođavanje intervala doziranja u bolesnika s klirensom kreatinina &lt; 50 ml/min, uključujući bolesnike na hemodijalizi.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half- life of &gt; 20 hours.
Telmisartan je karakteriziran bieksponencijalnom eliminacijskom farmakokinetikom, s terminalnim poluvijek eliminacije od &gt; 20 sati.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half- life of &gt; 20 hours.
Telmisartan je karakteriziran bieksponencijalnom eliminacijskom farmakokinetikom, s terminalnim poluvijekom eliminacije od &gt; 20 sati.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of &gt; 20 hours.
Za telmisartan je karakteristična bieksponencijalna farmakokinetika raspada, s terminalnim poluvremenom eliminacije od &gt; 20 sati.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of &gt; 20 hours.
Telmisartan je karakteriziran bieksponencijalnom eliminacijskom farmakokinetikom, s terminalnim poluvijekom eliminacije od &gt; 20 sati.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of &gt; 20 hours.
Telmisartan je karakteriziran bieksponencijalnom eliminacijskom farmakokinetikom, s terminalnim poluvremenom eliminacije od &gt; 20 sati.
Telmisartan is highly bound to plasma proteins ( &gt; 99.5 %) mainly albumin and alpha l- acid glycoprotein.
Telmisartan se uvelike veže na proteine plazme ( &gt; 99,5 %), uglavnom albumin i alfa 1 kiseli glikoprotein.
Telmisartan is highly bound to plasma proteins ( &gt; 99.5 %) mainly albumin and alpha l- acid glycoprotein.
Telmisartan se uvelike veže na proteine plazme ( &gt; 99,5%), uglavnom albumin i alfa 1 kiseli glikoprotein.
Telmisartan is highly bound to plasma proteins ( &gt; 99.5 %) mainly albumin and alpha l-acid glycoprotein.
Telmisartan se uvelike veže na proteine plazme ( &gt; 99,5%), uglavnom albumin i alfa 1 kiseli glikoprotein.
Telmisartan is largely bound to plasma protein ( &gt; 99.5%), mainly albumin and alpha-1 acid glycoprotein.
Telmisartan se uvelike veže na proteine plazme ( &gt; 99,5%), uglavnom albumin i alfa-1 kiselinski glikoprotein.
Telmisartan is largely bound to plasma protein ( &gt; 99.5 %), mainly albumin and alpha-1 acid glycoprotein.
Telmisartan se u velikoj mjeri veže na proteine plazme ( &gt; 99,5 %), uglavnom albumin i alfa-1 kiseli glikoprotein.
Telmisartan is largely bound to plasma protein ( &gt; 99.5 %), mainly albumin and alpha-1 acid glycoprotein.
Telmisartan se u velikoj mjeri veže na proteine plazme ( &gt; 99,5%), uglavnom albumin i alfa-1 kiseli glikoprotein.
Telmisartan is largely bound to plasma protein ( &gt; 99.5 %), mainly albumin and alpha-1 acid glycoprotein.
Telmisartan se uvelike veže na proteine plazme ( &gt; 99,5 %), uglavnom albumin i alfa-1 kiselinski glikoprotein.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose ( &gt; 97 %) was eliminated in faeces via biliary excretion.
Telmisartan: nakon i intravenske ili peroralne primjene 14C označenog telmisartana većina primijenjene doze ( &gt; 97 %) eliminira se fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose ( &gt; 97 %) was eliminated in faeces via biliary excretion.
Telmisartan: nakon i intravenske ili peroralne primjene 14C označenog telmisartana većina primijenjene doze ( &gt; 97%) eliminira se u fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose ( &gt; 97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C označenog telmisartana, većina primijenjen doze ( &gt; 97 %) eliminira se fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose ( &gt; 97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C označenog telmisartana, većina primijenjene doze ( &gt; 97 %) eliminira se fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose ( &gt; 97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C označenog telmisartana, većina primijenjene doze ( &gt; 97 %) eliminira se u fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose ( &gt; 97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C-označenog telmisartana, većina primijenjene doze ( &gt; 97%) eliminira se fecesom putem bilijarne ekskrecije.
Temporal association of olanzapine treatment and venous thromboembolism been reported uncommonly (≥ 0.1% and &lt; 1%).
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često ( &lt; 0,01 % i &lt; 1 %).
Temporal association of olanzapine treatment and venous thromboembolism been reported uncommonly (≥ 0.1% and &lt; 1%).
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često ( &lt; 0,01% i &lt; 1%).
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1 % and &lt; 1 %).
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) prijavljivana je manje često ( &lt; 0,01% i &lt; 1%).
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1% and &lt; 1%).
Manje često (≥ 0,1% i &lt; 1%) prijavljena je vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE).
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1% and &lt; 1%).
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) prijavljivana je manje često ( &lt; 0,01 % i &lt; 1 %).